

L84 ANSWER 1 OF 1 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 2003-221439 [21] WPIX  
 DNC C2003-056213  
 TI Reducing mammalian hair growth comprises applying telomerase inhibitor to selected skin area.  
 DC B05 D16 D21  
 IN AHLUWALIA, G S; STYCZYNSKI, P  
 PA (AHLU-I) AHLUWALIA G S; (STYC-I) STYCZYNSKI P; (GILL) GILLETTE CO  
 CYC 101  
 PI WO 2003002077 A2 20030109 (200321)\* EN 7 A61K007-00  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
 NL OA PT SD SE SL SZ TR TZ UG ZM ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR  
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT  
 RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM  
 ZW  
 US 2003012755 A1 20030116 (200321) A61K048-00  
 EP 1401379 A2 20040331 (200424) EN A61K007-00  
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT  
 RO SE SI TR  
 ADT WO 2003002077 A2 WO 2002-US18702 20020612; US 2003012755 A1 US 2001-893252  
 20010627; EP 1401379 A2 EP 2002-734785 20020612, WO 2002-US18702 20020612  
 FDT EP 1401379 A2 Based on WO 2003002077  
 PRAI US 2001-893252 20010627  
 IC ICM A61K007-00; A61K048-00  
 ICS A61K007-06; A61K031-19; A61K031-4745; A61K031-56  
 AB WO2003002077 A UPAB: 20030328  
 NOVELTY - Reducing hair growth comprises applying a telomerase inhibitor to a selected area of skin.  
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:  
 (1) reducing mammalian hair growth which comprises selecting an area of skin including hair follicles and applying a compound that reduces telomerase levels, telomerase mRNA expression or promotes the erosion of telomeric DNA in the hair follicles to the skin, and  
 (2) a composition comprising the telomerase inhibitor, a carrier and at least one of an emollient, thickener, humectant, powder or skin penetration aid.  
 ACTIVITY - None given in the source material.  
 MECHANISM OF ACTION - Telomerase inhibitor.  
 A composition containing AZT (10 weight%) in vehicle containing water (68%), ethanol (16%), propylene glycol (15%), dipropylene glycol (5%), benzyl alcohol (4%) and propylene carbonate (2%) was tested using Golden Syrian Hamster assay. A vehicle containing AZT (10%) was applied to an organ of the animal. Inhibition of flank organ hair growth was demonstrated following the topical administrable of the composition. The reduction of hair growth was calculated after applications (one application per day for 5 days a week). The hair mass value was 2.10 plus or minus 1.8 mg and percentage inhibition was 22 plus or minus 7.  
 USE - Used for reducing unwanted mammalian (e.g. human) hair growth (preferably androgen stimulated hair growth) and in a cosmetic (claimed).  
 ADVANTAGE - The composition reduces hair growth by at least 15 (preferably 20)% when tested in the Golden Syrian Hamster assay.  
 Dwg. 0/0  
 FS CPI

FA AB; DCN

MC CPI: B01-D02; B02-E; B02-P; B04-B03A; B04-B03C; B04-E01; B06-D02; B06-D09;  
B06-D18; B07-A04; B08-B; B10-E04; B14-D06B; B14-R02; D05-H12A;  
D05-H12D; D08-B07

TECH UPTX: 20030328

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Components: The telomerase inhibitor comprises floxacin, TMPyP4, telomerase inhibitor I, telomerase inhibitor IV, telomerase inhibitor V, AZT, rubromycin, purpuromycin, 3'-deoxy-2:3'-didehydrothymidine, dideoxyinosine, (TTAGGG)3, levofloxacin, carbovir, ACGTTGAGGGGCATC, 2-(3(trifluoromethyl)phenyl)isothiazolin-3-one, ursodeoxycholic acid, diazaphilonic acid, alterperyleneol, 5-azacytidine, 3,4,9,10-perylene tetra carboxylic diimide-based ligand, 10H-indolo(3,2-b)quinoline, 2'-O-MeRNA telomerase oligomer, 2'-O-alkyl RNA telomerase oligomer, fomivirsen, a cationic porphyrin, diazaphilonic acid, telomerase inhibitor II, telomerase inhibitor III, telomerase inhibitor VI, telomerase inhibitor VII or telomerase inhibitor VIII.

Preferred Composition: The composition also includes a second component that also causes a reduction in hair growth.

ABEX UPTX: 20030328

ADMINISTRATION - The application amount is 10-3000 mug/cm<sup>2</sup> topically to the skin of the face, a leg, an arm, an armpit or on the torso, or in conjunction with the shaving or a woman with hirsutism (claimed).

=>